Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. (2nd September 2018)

• Record Type: Journal Article
• Authors: Zhu, Gui-Qi; Sun, Min; Liao, Wei-Ting; Yu, Wei-Hua; Zhou, Shao-Lai; Zhou, Zheng-Jun; Shi, Ying-Hong; Fan, Jia; Zhou, Jian; Qiu, Li-Xin; Dai, Zhi
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 12:Number 9(2018)
• Page Start: 935
• Page End: 945
• Publication Date: 2018-09-02
• Subjects: Small hepatocellular carcinoma -- network meta-analysis -- randomized controlled trials -- ablative therapy -- liver resection; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2018.1503531
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Background : Major treatments for small hepatocellular carcinoma (SHCC) include percutaneous ethanol injection (PEI), percutaneous acetic acid injection (PAI), radiofrequency ablation (RFA), or surgical resection (SR). We aimed to compare these therapies concerning with effectiveness and safety. Methods : Cochrane Library, PubMed, and Embase were searched for randomized controlled studies (RCTs) from inception to 30 April 2017. Odds ratios (OR) for proportion dead (PD), local recurrence (LR) and adverse events (AEs). Results : Fourteen RCTs were identified. Compared with SR, PEI (OR 2.79, CrI 1.25, 6.45, p < 0.01) provided a significantly increased risk of PD. Similarly, PEI (OR 4.29, CrI 1.18, 18.35, p < 0.01) yielded more LR than SR. Also, SR significantly conferred more AEs than RFA (OR 0.10; CrI 0.02, 0.35, p < 0.01), PEI (OR 0.06; CrI 0.01, 0.31, p < 0.01). Besides, RFA conferred the highest efficacy for survival, time to recurrence, and new development of HCC. Conclusions : SR was superior to PEI. Although SR achieved highest cumulative ranking probabilities in clinical efficacy, it obtained a low benefit-to-risk ratio for patients. RFA was superior to the other ablative therapies. For tumor sizes > 2 cm or ≤ 2 cm in diameter, SR conferred non-significant effects compared with other therapies for SHCC.